Bead layering as a process to stabilize nanosuspensions: Influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 11, 2011, Pages 1446-1453

  Kayaert, Pieterjan ^a   Anné, Michaël ^a   Van Den Mooter, Guy ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

bead layering; cinnarizine; coating; nanosuspension; naproxen

Indexed keywords

CINNARIZINE; HYDROXYPROPYLMETHYLCELLULOSE; NANOCRYSTAL; NAPROXEN; STABILIZING AGENT; SUGAR; TOCOFERSOLAN;

ARTICLE; CONTROLLED STUDY; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FLUIDIZED BED; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IN VITRO STUDY; NANOFABRICATION; NANOPHARMACEUTICS; NANOSUSPENSION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PREDICTION; SLOW DRUG RELEASE; SOLID STATE; SPRAY DRYING; SURFACE PROPERTY; SUSPENSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM CHANNEL BLOCKERS; CINNARIZINE; DESICCATION; DRUG STABILITY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, THEORETICAL; NANOPARTICLES; NAPROXEN; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES; SUSPENSIONS;

EID: 80054099463     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01351.x     Document Type: Article

References (19)

1. Lipinski CA,. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249. (Pubitemid 32239479)
2. Lipinski CA,. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 2002; 5: 82-85.
3. Humberstone AJ, Charman WN,. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25: 103-128.
4. Leuner C, Dressman J,. Improving drug solubility for oral delivery using solid dispersions. Int J Pharm 2000; 50: 47-60. (Pubitemid 30326688)
5. Müller RH, Peters K,. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm 1998; 160: 229-237. (Pubitemid 28083096)
6. Van Eerdenbrugh B, et al,. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
7. Kipp JE,. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004; 284: 109-122. (Pubitemid 39349144)
8. Jinno J, et al,. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111: 56-64. (Pubitemid 43289995)
9. Liversidge GG, Conzentino P,. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995; 125: 309-313.
10. Abdelwahed W, et al,. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006; 58: 1688-1713. (Pubitemid 44827432)
11. Rabinow BE,. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-796. (Pubitemid 39242830)
12. Chaubal M, Popescu C,. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res 2008; 25: 2302-2308.
13. Müller RH, et al,. Manufacturing of nanoparticles by milling and homogenization techniques. In:, Gupta RB, Kompella UB, eds. Nanoparticle Technology for Drug Delivery. New York: Taylor and Francis Group, 2006: 21-51.
14. Möschwitzer J, Müller RH,. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm 2006; 62: 282-287. (Pubitemid 43356577)
15. Olver I, et al,. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine 2007; 2: 13-18. (Pubitemid 46901776)
16. Basa S, et al,. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm 2008; 34: 1209-1218.
17. Van Eerdenbrugh B, et al,. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci 2009; 98: 2091-2103.
18. Kayaert P, et al,. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions. Eur J Pharm Biopharm 2010; 76: 507-513.
19. Van Eerdenbrugh B, et al,. Drying of crystalline drug nanosuspensions: the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 2008; 35: 127-135.